study_id,drug,subject_id,age_years,age_days,weight_kg,cl_l_per_h_per_kg,t_half_h,route,aggregated_row,notes,source,source_file,age_group,cl_ml_per_min_per_kg,cl_l_per_h,cmin_ng_per_ml,visit,dose_mg,auc_mg_h_per_l,cmax_mg_per_l,route_harmonized,pathway,pathway_harmonized,age_group_pbpk
vet_et_al_2014_agg,midazolam,,2.0,730.0,12.0,0.28,,iv,True,Critically ill children median clearance (group summary),https://pmc.ncbi.nlm.nih.gov/articles/PMC3948203/,midazolam_raw.csv,,,,,,,,,intravenous,CYP3A4 hepatic metabolism,hepatic_CYP3A4,child
metoprolol_fda_bpca,metoprolol,meto_1,7.0,,,,4.0,oral,True,FDA BPCA summary Cmin values; high variability reported,https://www.fda.gov/files/drugs/published/019962s033-Metoprolol-Clinpharm-BPCA.pdf,metoprolol_raw.csv,,,,12.2,,,,,oral,,,child
metoprolol_fda_bpca,metoprolol,meto_3,3.0,,,,4.0,oral,True,FDA BPCA summary Cmin values; high variability reported,https://www.fda.gov/files/drugs/published/019962s033-Metoprolol-Clinpharm-BPCA.pdf,metoprolol_raw.csv,,,,8.5,,,,,oral,,,child
